Abeona Therapeutics (NASDAQ:ABEO) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research note released on Thursday morning, Benzinga reports. The firm currently has a $15.00 price target on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday. StockNews.com upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 10th.

Abeona Therapeutics Trading Down 1.7 %

Shares of NASDAQ ABEO traded down $0.11 during mid-day trading on Thursday, hitting $6.30. 34,718 shares of the company were exchanged, compared to its average volume of 435,081. The company has a debt-to-equity ratio of 0.22, a current ratio of 7.48 and a quick ratio of 7.48. The stock has a 50 day simple moving average of $6.02 and a 200-day simple moving average of $5.18. Abeona Therapeutics has a 1-year low of $3.05 and a 1-year high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.42). Equities analysts predict that Abeona Therapeutics will post -1.28 earnings per share for the current fiscal year.

Institutional Trading of Abeona Therapeutics

Several institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp lifted its holdings in shares of Abeona Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock valued at $515,000 after buying an additional 2,434 shares during the period. Acadian Asset Management LLC acquired a new position in Abeona Therapeutics during the first quarter valued at $91,000. Rosalind Advisors Inc. boosted its stake in shares of Abeona Therapeutics by 4.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after acquiring an additional 82,000 shares in the last quarter. abrdn plc raised its position in Abeona Therapeutics by 158.8% in the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after purchasing an additional 200,647 shares during the last quarter. Finally, Simplify Asset Management Inc. bought a new position in Abeona Therapeutics in the 2nd quarter valued at $1,732,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.